Beta-Secretase Modulators for Alzheimer's Plaque Reduction

The patent applies parameter changes by modifying the chemical structure of beta-secretase inhibitors to achieve different binding modes and enzymatic inhibition mechanisms. The compounds feature diverse structural parameters including varying core structures (pyridine, pyrimidine, triazine rings), substituent positions, and chain lengths that collectively optimize both plaque reduction and disease progression control through enhanced enzyme inhibition efficacy

The patent employs composite materials by creating molecules with multiple functional groups and complex structural compositions. Each compound integrates heterocyclic cores with various substituents (halogens, alkyl groups, alkoxy groups, nitro groups) to form composite molecular structures that simultaneously achieve high binding affinity to beta-secretase and improved pharmacological properties for better disease progression control

The patent applies segmentation by dividing the molecular structure into distinct functional modules: a core heterocyclic unit (pyridine, pyrimidine, or triazine ring), intermediate linker chains with specific carbon lengths, and terminal functional groups. This modular segmentation allows systematic optimization of each segment's contribution to binding affinity while maintaining overall structural manageability and synthetic feasibility

The patent implements local quality by introducing specific functional groups at particular positions on the core ring structure. For example, halogen atoms (fluoro, chloro, bromo) are placed at specific ring positions to enhance binding affinity locally, while alkyl and alkoxy substituents are positioned to optimize solubility and metabolic stability without requiring complete structural redesign